Today: 14 May 2026
Browse Category

Pharmaceuticals 9 December 2025 - 11 December 2025

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals shares fell 6% to US$9.33 in New York on December 11, near a 52-week low, despite trailing 12-month revenue of US$664 million and a new clinical partnership with Varian. The company faces SEC scrutiny, an FDA setback, and multiple class-action lawsuits, but continues to report late-stage oncology progress and expanding collaborations.
11 December 2025
···
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant shares rose 9% to $25.75 Thursday after the company announced a $550 million common stock offering to fund development and possible launch of its lead drug, IMVT‑1402, for Graves’ disease. The offering priced at $21 per share, an 11% discount, and is expected to close December 12. Roivant Sciences will participate. Immunovant’s market value reached about $4 billion.
11 December 2025
····
AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie shares rebounded 2.98% to $236.28 on Nov. 21, 2025, with trading volume spiking to 7.9 million after three down days. Year-to-date, the stock is up about 22–26%, outpacing the S&P 500, but remains 7–9% below its October high. Forward P/E estimates range from 16x to 22x. Investors weigh strong Skyrizi and Rinvoq sales against Humira declines and regulatory risk.
11 December 2025
···
Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market value on November 21, 2025, driven by strong demand for its obesity and diabetes drugs. By December 11, shares traded near $993, with a market cap of about $890 billion, down from the peak. The company’s stock is up over 550% in five years, far outpacing the S&P 500. Investors are now focused on valuation rather than growth.
11 December 2025
··
Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer shares traded near $25.78 early Thursday, flat from Wednesday’s close, after hedge fund Marshall Wace disclosed a 96.8% reduction in its stake. The stock remains over 50% below its December 2021 high. Pfizer’s 52-week range is $20.92 to $27.69, with a market cap near $147 billion and a dividend yield around 6.7%.
11 December 2025
··
Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer shares traded near $25.5 on December 10, up less than 1% but still over 50% below their 2021 peak. The company announced a $2.1 billion obesity-drug partnership with China’s YaoPharma, reported Phase 3 wins for TUKYSA and HYMPAVZI, and confirmed new job cuts in Switzerland. Dividend yield stands near 6.7%. Pfizer reaffirmed 2025 adjusted EPS guidance at $3.00–$3.15.
10 December 2025
··
Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Olema Pharmaceuticals (NASDAQ: OLMA) surged over 11% to $29.68 on December 10, 2025, hitting a new 52-week high amid heavy trading. The rally followed positive Phase 3 data from Roche’s breast cancer drug trial, which boosted confidence in Olema’s own SERD candidate. Year-to-date, OLMA shares have climbed over 400%, with market cap reaching $2.37 billion.
10 December 2025
·
Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck shares traded near $97.31 Wednesday afternoon, up slightly after Tuesday’s 2% drop. Volume topped 3.2 million as investors tracked dividend moves and new analyst upgrades. The stock remains about 25% below 2024 highs despite a 41% six-month rally. Signs of rising competition to Keytruda and looming patent pressures weighed on sentiment.
10 December 2025
··
Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson shares rose nearly 2% to about $204 on December 10, 2025, after new Phase 3 data showed its Tecvayli and Darzalex combo cut the risk of multiple myeloma progression or death by 83%. The company has filed for FDA approval, while investors weigh growth in oncology against ongoing talc litigation. JNJ stock is up over 38% year to date, outpacing healthcare peers.
10 December 2025
···
Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck shares traded near $97.27 late December 10, 2025, up about 20% over the past month on strong clinical trial results and optimism for new products like Winrevair. Analysts at HSBC, Guggenheim, Scotiabank, and Goldman Sachs raised 12-month price targets to $120–$125. Merck’s market value stands at $240–245 billion, with a dividend yield of about 3.4–3.6%.
10 December 2025
···
Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk shares rose about 3–4% to $48 in New York trading on December 10 after months of steep losses. The move followed an Argus downgrade to Hold, citing GLP-1 market-share erosion and underwhelming trial results. Novo has submitted a higher-dose Wegovy application to the FDA. Shares remain down nearly 59% over the past year.
10 December 2025
··
Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva shares traded near $29, close to 52-week highs, after filing a new FDA application for a once-monthly schizophrenia drug and receiving analyst upgrades. Market cap stands at about $32–33 billion. The company reported improved debt ratios and expects consensus 2025 EPS of $2.70. Technical indicators show the stock as overbought but still in an uptrend.
10 December 2025
··
Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly shares traded near $980 midday Monday, after briefly surpassing $1,050 and becoming the first healthcare firm valued above $1 trillion. Q3 revenue rose 54% to $17.6 billion, fueled by Zepbound and Mounjaro sales topping $10 billion. The company announced a $6 billion Alabama plant for its oral weight-loss drug and completed its Adverum Biotechnologies acquisition. LLY trades at about 49 times trailing earnings, far above big-pharma averages.
10 December 2025
··
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) traded around $0.69 per share mid-session December 10, up 10% on the day but still down 72% over the past year. Market cap stood near $78–80 million. On December 9, call options volume spiked 458% above average as traders speculated on upcoming catalysts. The company’s lead drug, brilaroxazine, recently completed Phase 3 trials in schizophrenia.
10 December 2025
··
Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) closed at $4.09 on December 9, down 53.5% from the prior session, after wild swings that saw the stock trade between $4.00 and $7.60 intraday. The company is advancing a Phase 3 trial in a rare inherited cancer syndrome and exploring new financing. Its float remains under 670,000 ADSs, fueling extreme volatility. Market cap stands near $5.5 million.
10 December 2025
··
GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

The US FDA granted Orphan Drug Designation to GSK’s experimental lung cancer therapy risvutatug rezetecan on December 10. GSK shares traded near 1,780 pence in London, up about 29% over 12 months. The drug targets small-cell lung cancer and has shown durable responses in early trials. GSK’s US ADR closed at $47.27, near its 52-week high.
10 December 2025
···
Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Merck shares closed down 2.06% at $96.89 on December 9, 2025, with volume spiking to 15.3 million shares. The drop followed news that Formycon and Zydus Lifesciences will partner on a biosimilar to Merck’s top-selling cancer drug Keytruda, targeting the U.S. and Canada. Keytruda generated $29.5 billion in 2024 sales. Merck and JPMorgan were among the biggest drags on the Dow, which fell 0.8%.
10 December 2025
··
Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly will invest over $6 billion to build a pharmaceutical manufacturing campus in Huntsville, Alabama, creating 450 permanent and 3,000 construction jobs. The 260-acre facility will produce active ingredients for small-molecule and peptide medicines, including the oral GLP-1 obesity drug orforglipron. Construction is set to begin in 2026 and finish by 2032. State officials call it Alabama’s largest-ever private industrial investment.
10 December 2025
·
Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals shares traded at $26–27 on December 9, up over 800% from their 52-week low but 12% below the recent high. The stock surged after Roche’s positive Phase 3 results for a similar breast cancer drug, triggering analyst upgrades and price target hikes. Market capitalization now stands near $2–2.2 billion. Analyst 12-month targets range from $20 to $55, with most rating the stock a strong buy.
9 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals stock surged to a 52-week high of $71.5 on December 8, 2025, after securing its first FDA approval for REDEMPLO and announcing a major Novartis licensing deal. Shares traded around $69 on December 9, up over 260% year-to-date, with market value near $9.5 billion. Trading volume more than doubled typical levels. The company also began dosing in an Alzheimer’s trial.
9 December 2025
··
1 … 28 29 30 31 32 … 40

Stock Market Today

  • NVIDIA Stock Rises 2.29% with Strong Technical Indicators but Volume Divergence Signals Caution
    May 13, 2026, 10:42 PM EDT. NVIDIA's stock price increased 2.29% on May 13, 2026, continuing a six-day winning streak and rising 7.92% over two weeks. Notably, the stock broke a strong short-term trend line at $223.03, suggesting further gains toward the $264.30 resistance level. Moving averages signal a buy, with the short-term trend above the long-term. However, declining volume despite rising prices may indicate a potential reversal. Support levels are identified at $213.87, $195.72, and $184.89, with sell signals triggered if these break. Technical caution is advised due to a sell signal from the 3-month MACD indicator and volume-price divergence. Market watchers should monitor NVIDIA closely for short-term shifts amid medium risk trading conditions.

Latest articles

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

14 May 2026
Enovix shares dropped 12.9% to $6.35 after hours Wednesday despite beating first-quarter revenue and adjusted-loss estimates. The decline followed news that smartphone battery qualification remains unfinished, with the company passing 72 of 75 customer tests. Revenue rose 49% to $7.6 million. Enovix cited progress in defense, industrial, and smart-eyewear sales.
Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

14 May 2026
Lightwave Logic reported Q1 revenue up 27% to $29,000 and a net loss widening to $6.3 million. Shares rose 14% after the company said it is negotiating a supply and licensing deal for high-volume production in 2027. Four Fortune 500 customers are now in Stage 3 prototyping. Cash and equivalents totaled about $100 million as of May 11.
USA Rare Earth Stock Watch: Q1 Revenue, $1.75 Billion Cash and the China Supply Crunch

USA Rare Earth Stock Watch: Q1 Revenue, $1.75 Billion Cash and the China Supply Crunch

14 May 2026
USA Rare Earth reported Q1 revenue of $5.7 million and a net loss of $67 million, ending March with $1.75 billion in cash after a $1.5 billion PIPE. The company expects to sign documents this month for $1.6 billion in U.S. Commerce Department funding. Texas awarded a $14.18 million grant for the Round Top project. USA Rare Earth agreed in April to acquire Brazil’s Serra Verde for $2.8 billion.
Go toTop